BSE · 524731
Jenburkt Pharmaceuticals Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹158 Cr with net profit ₹32 Cr — a 20.24% net margin, versus 17.72% the period before.
Shareholding
As of 2026-06-30
- Promoter46.62%
- Public53.26%
- DII0.12%
7,103 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.42× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #20 of 50 by market cap · medians across 41 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,85,513 Cr | 84.64 | 22.06 | 25.49% | 15.55% |
| Ajanta Pharma Limited | ₹42,241 Cr | 158.36 | 9.36 | 23.33% | 19.37% |
| Gland Pharma Limited | ₹41,784 Cr | 113.79 | 4.03 | 9.92% | 15.98% |
| Rubicon Research Limited | ₹25,235 Cr | 327.29 | 19.62 | 19.14% | 14.07% |
| Eris Lifesciences Limited | ₹19,762 Cr | 69.23 | 5.06 | 15.87% | 19.89% |
| Caplin Point Laboratories Ltd. | ₹19,733 Cr | 116 | 5.5 | 17.88% | 29.32% |
| Shilpa Medicare Ltd. | ₹11,869 Cr | 110.14 | 4.58 | 9.39% | 15.81% |
| Marksans Pharma Limited | ₹11,789 Cr | 79.56 | 3.9 | 13.82% | 14.16% |
| Senores Pharmaceuticals Limited | ₹6,062 Cr | 165.35 | 6.49 | 12.36% | 18.32% |
| Bliss GVS Pharma Ltd. | ₹4,884 Cr | 143.01 | 4.08 | 8.95% | 11.15% |
| Jenburkt Pharmaceuticals Ltd.(this company) | ₹468 Cr | 12.44 | 2.37 | 17.63% | 20.58% |
AI analysis
AI-generated · google/gemini-2.5-flashJenburkt Pharmaceuticals Ltd. is listed on the Indian markets with a market capitalization of Rs 481 Cr. The company reported annual revenue of Rs 158.41 Cr in Mar 2025 and a net profit of Rs 32.06 Cr in the same period. Its EPS for Mar 2025 was Rs 72.65, contributing to a current PE ratio of 12.8. The company has a book value of Rs 446.48 and a low debt-to-equity ratio of 0.01.
Positives
- +The company has a high profit margin of 20.58%.
- +Return on equity (ROE) is 17.63%.
- +Return on capital employed (ROCE) is 23.196%.
- +The debt-to-equity ratio is low at 0.01.
- +Promoter shareholding is not pledged (0%).
Negatives
- −Promoter holding of 46.6193% as of Jun 2026 is lower than DII and FII holdings, as FII holding is 0% and DII holding is 0.1213%.
- −Quarterly EPS data is not available for any reported quarter.
Financial Performance
Jenburkt Pharmaceuticals Ltd. has shown growth in its annual revenue over the past five years, increasing from Rs 113.60 Cr in Mar 2021 to Rs 158.41 Cr in Mar 2025. Net profit also rose from Rs 16.50 Cr in Mar 2021 to Rs 32.06 Cr in Mar 2025. Earnings per share (EPS) grew from Rs 35.96 in Mar 2021 to Rs 72.65 in Mar 2025, indicating consistent profitability.
Profitability & Returns
The company reported a profit margin of 20.58%. Return on equity (ROE) stood at 17.63% and return on capital employed (ROCE) was 23.196%. These figures suggest efficient use of shareholder funds and capital in generating profits. The company's EPS was Rs 85.23, contributing to its overall profitability.
Balance Sheet
Jenburkt Pharmaceuticals Ltd. maintains a very low debt-to-equity ratio of 0.01, indicating minimal reliance on borrowed capital. The book value per share is Rs 446.48. This strong financial position suggests a conservative approach to financing operations.
Ownership & Pledges
As of June 2026, promoters held 46.6193% of the company's shares. Public shareholding was 53.2594%, while institutions, specifically DIIs, held 0.1213%. There were no promoter pledges reported, indicating no shares were encumbered. The total number of shareholders was 7103.
Regulatory & Surveillance
No information regarding regulatory actions or surveillance measures was provided for Jenburkt Pharmaceuticals Ltd. Shares traded in a 52-week range between Rs 944 and Rs 1364.9.
Data as of — price: 2026-07-29 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Jenburkt Pharmaceuticals Ltd.share price & fundamentals